EC Number |
Substrates |
Organism |
Products |
Reversibility |
---|
2.4.1.244 | UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside |
51.7% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
Homo sapiens |
UDP + GalNAc-beta(1,4)-Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside |
- |
? |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
16.2% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
Homo sapiens |
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
? |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
21.6% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
Homo sapiens |
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
? |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside |
3.4% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
Homo sapiens |
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
? |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside |
5% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
Homo sapiens |
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
? |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside |
- |
Drosophila melanogaster |
UDP + GalNAc-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
? |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
Homo sapiens |
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
? |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside |
76.8% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
Homo sapiens |
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
? |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside |
87.1% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
Homo sapiens |
UDP + GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
? |
2.4.1.244 | UDP-GalNAc + GlcNAc-beta-(1,3)-GalNAc-alpha-p-nitrophenyl |
- |
Drosophila melanogaster |
UDP + GalNAc-beta-(1,4)-GlcNAc-beta-(1,3)-GalNAc-alpha-p-nitrophenyl |
- |
? |